A third of adult leukemia patients given the novel drug quizartinib during a phase II study have achieved a composite response of either complete remission, or remission with incomplete platelet recovery or incomplete hematologic recovery, report US researchers.
via Med Wire News
via Med Wire News
No comments:
Post a Comment